Sign inJoin waitlistJoin the waitlist

Aaron Sugalski

Medical Director · University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine

Credentials: · · · ·

History

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
Present
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
Present

Pediatric Hematology/Oncology
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
2009–2012
Pediatrics
University of Texas Health Science Center at San Antonio
2006–2009
Internal Medicine
A.T. Still University-Kirksville College of Osteopathic Medicine
2003–2006
A.T. Still University Kirksville College of Osteopathic Medicine
2002–2006
Texas A&M University
1999

Research

Facilitators and barriers to clinical practice guideline-consistent supportive care at pediatric oncology institutions: a Children's Oncology Group study
Implementation Science Communications · 2021 · First of 13 authors · 27 citations
In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma
Oncoscience · 2014 · 26 citations
Rationale and design of Children's Oncology Group (COG) study ACCL20N1CD: financial distress during treatment of acute lymphoblastic leukemia in the United States
BMC Health Services Research · 2022 · 15 citations

MB
Melissa Beauchemin
9 papers
Allison Grimes
8 papers
Susan Parsons
7 papers
AL
Anne Marie Langevin
6 papers
Alexandra Walsh
5 papers
Lolie Yu
5 papers
Gail Tomlinson
4 papers
Brian Fisher
3 papers
YC
Yidong Chen
3 papers
Josefine Heim-Hall
2 papers
Julie Wolfson
2 papers
Michael Roth
2 papers

Clinical trials

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2026–2029
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029